ASCO 2023 | Top highlights from ASCO & EHA 2023
Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, shares his enthusiasm for advances in the field of hematological oncology presented at this year’s ASCO and EHA meetings. Prof. Mohty comment on immune therapy advances in myeloma and lymphoma, as well as the use of checkpoint inhibitors in the frontline setting in Hodgkin lymphoma (HL), and the use of luspatercept in myelodysplastic syndromes (MDS). This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Gilead: Honoraria; GSK: Honoraria; Pfizer,: Honoraria; Adaptive Biotechnologies: Honoraria; Oncopeptides: Honoraria; Astellas: Honoraria; Novartis: Honoraria; Takeda: Honoraria; Amgen: Honoraria; Jazz Pharmaceuticals: Honoraria, Research Funding; Celgene: Honoraria; Bristol Myers Squibb: Honoraria; Sanofi: Honoraria, Research Funding; Janssen: Honoraria, Research Funding.
